High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190 PURPOSE: To characterize the pharmacokinetics of topotecan in a population model that ...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
Models were fitted to population data using NMQUAL (https://metruminstitute.org/index.html-validated installation of the NONMEM, version V, level 1.1; GloboMax ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback